AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30548111
Drug: Activity-oriented therapy
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity-oriented therapy (cooking)
Trial: 29706047
Drug: Qilin Pills
RxNorm normalized name: Qilib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qilin Pills (6 g tid for 12 weeks)
Trial: 29706047
Drug: Wuziyanzong Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuziyanzong Pills (6 g bid for 12 weeks)
Trial: 23400750
Drug: Intravaginal taggant
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal taggant (2‐butyl acetate, 2‐pentyl acetate, isopropyl butyrate, or 2‐pentyl butyrate; 30 mg) in hydroxyethylcellulose or tenofovir placebo gel
Trial: 23400750
Drug: Dermal administration
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermal administration of the same formulations
Trial: 20512389
Drug: Test tablets
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test tablets containing bovine lactoferrin and lactoperoxidase
Trial: 19250310
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of BoNT‐A (20 U and 30 U)
Trial: 17295590
Drug: diazepam 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam 0.1 mg/kg
Trial: 8442971
Drug: diazepam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam 0.3 mg/kg
Trial: 9621667
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg.kg‐1) with lidocaine (group ML)
Trial: 9621667
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg.kg‐1) (group L)
Trial: 30792007
Drug: BUP‐XR 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP‐XR 300 mg/300 mg
Trial: 30792007
Drug: BUP‐XR 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP‐XR 300 mg/100 mg
Trial: 30107404
Drug: Fronto-temporal transcranial
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fronto-temporal transcranial direct current stimulation (tDCS) with 2-mA, twice-daily sessions for 5 consecutive days.
Trial: 26735919
Drug: 2-hour reduction
RxNorm normalized name: REDUCTIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour reduction in daily sitting
Trial: 22551119
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of 150 ml tomato juice (15 mg lycopene) for 5 weeks
Trial: 10465129
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g three times daily
Trial: 10465129
Drug: Cefepime 2
RxNorm normalized name: cefepime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 2 g twice daily
Trial: 157076
Drug: Metronidazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (200 mg or 400 mg three times daily for 10 days)
Trial: 25787200
Drug: fasiglifam 50
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fasiglifam 50 mg
Trial: 25787200
Drug: fasiglifam 25
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fasiglifam 25 mg
Trial: 18824040
Drug: Cortisol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (30 mg oral dose)
Trial: 15538933
Drug: GHRH antagonist
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH antagonist (N‐Ac‐Tyr(1), D‐Arg(2)) GHRH‐29 (NH(2))
Trial: 11288008
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (18 patients)
Trial: 9040547
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of zinc per day for the first 3 days of TPN
Trial: 9040547
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg of zinc per day for the first 3 days of TPN
Trial: 30115054
Drug: Daily Physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Physical Activity (DPA) program consisting of 20 minutes of teacher-led DPA for 20 consecutive weeks
Trial: 26280577
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (LDA)
Trial: 25742320
Drug: Mobile phone
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile phone intervention (customised, interactive, automated voice reminders sent weekly)
Trial: 22943559
Drug: Rectal TFV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal TFV 1% gel (7-day exposure)
Trial: 22943559
Drug: Rectal TFV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal TFV 1% gel (single exposure)
Trial: 22943559
Drug: Rectal TFV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal TFV 1% gel (single and 7-day exposure)
Trial: 22943559
Drug: Oral TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TDF (300 mg single exposure)
Trial: 22943559
Drug: Hydroxyethyl cellulose
RxNorm normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl cellulose (HEC) placebo gel
Trial: 11958408
Drug: Bioactive glass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioactive glass grafting material used in dental implants
Trial: 10418907
Drug: DTwP//PRP‐T vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP//PRP‐T vaccine (group A, N = 85)
Trial: 10418907
Drug: DTwP//Placebo vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP//Placebo vaccine (group B, N = 83)
Trial: 10418907
Drug: DT booster
RxNorm normalized name: L-DT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: DT booster dose at age 5 years (subgroup B1)
Trial: 10418907
Drug: Hib polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib polysaccharide (PRP) vaccine (subgroups A2 and B2)
Trial: 1705089
Drug: Thrombin infusion
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin infusion via a four-way balloon catheter (5,000 U in 5 ml of saline)
Trial: 1705089
Drug: Thrombin infusion
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin infusion group
Trial: 26687697
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil (2400 mg/d; DHA: 1450 mg, EPA: 400 mg)
Trial: 12867218
Drug: IM olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM olanzapine 10 mg
Trial: 3777553
Drug: Intranasal nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal nifedipine (10 mg)
Trial: 3777553
Drug: Intravenous diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diltiazem (0.3 mg X kg‐1 followed by continuous infusion of 3 micrograms X kg‐1 X min‐1)
Trial: 16330196
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preventive treatment)
Trial: 26902281
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg/day) plus Risperidone (up to 6 mg/day)
Trial: 26902281
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Risperidone (up to 6 mg/day)
Trial: 19013980
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose mitomycin C (MMC) administered to 49 patients
Trial: 19013980
Drug: No mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No mitomycin C administered to 51 patients
Trial: 10440419
Drug: Clopidogrel 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 100 mg
Trial: 10440415
Drug: Clopidogrel 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 200 mg
Trial: 10440415
Drug: Clopidogrel 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 400 mg
Trial: 10440415
Drug: Clopidogrel (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (400 mg, capsules and tablets)
Trial: 1899364
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg rt-PA with heparin and aspirin
Trial: 30477911
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) plus masking therapy and sound treatment
Trial: 30477911
Drug: Masking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masking therapy and sound treatment
Trial: 27730478
Drug: Action Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action Observation Training (AOT-G)
Trial: 27730478
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (C-G)
Trial: 24655622
Drug: Fluoxetine 20-40mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20-40mg/day
Trial: 15277317
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg/d for 6 months
Trial: 17519271
Drug: Oral leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral leflunomide (LEF) 30 mg/day
Trial: 17519271
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (MTX) starting with 7.5 mg/week reaching 20 mg/week after 8 weeks
Trial: 11293554
Drug: Adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene gel (0.1%)
Trial: 11293554
Drug: Adapalene cream
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene cream (0.1%)
Trial: 11293554
Drug: Erythromycin (4%)/tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (4%)/tretinoin (0.025%) solution
Trial: 11293554
Drug: Erythromycin (4%)/tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (4%)/tretinoin (0.025%) gel
Trial: 11293554
Drug: Erythromycin (2%)/isotretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (2%)/isotretinoin (0.05%) gel
Trial: 7697479
Drug: Intranasal ragweed
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ragweed challenge (doses 10, 100, and 1000 PNU)
Trial: 24252717
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal Oxytocin administration
Trial: 22077070
Drug: Daily azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily azithromycin
Trial: 17188409
Drug: Amoxicillin 2g
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 2g combined with clavulanic acid, orally daily for 5 days postoperatively
Trial: 17188409
Drug: Amoxicillin 2g
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 2g combined with clavulanic acid, starting 5 days before the operation
Trial: 15654549
Drug: 44 mcg
RxNorm normalized name: Tirosint 44 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 mcg subcutaneously three times weekly (tiw)
Trial: 15654549
Drug: 30 mcg
RxNorm normalized name: Avonex 30 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mcg intramuscularly once weekly (qw)
Trial: 11238511
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) (400-600 IU/day) and calcium (500 mg/day)
Trial: 9550248
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management plus marital intervention for 11 months
Trial: 9550248
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management plus marital intervention
Trial: 7942680
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg each morning
Trial: 3227297
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg oral propranolol twice daily for 7 days
Trial: 3227297
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 7 days
Trial: 2232492
Drug: Sham hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham hemodialysis with indomethacin administration (Group CU-IND)
Trial: 4916211
Drug: Inert tablets
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert tablets (placebo)
Trial: 17557470
Drug: Zaleplon 10
RxNorm normalized name: zaleplon 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon 10 mg
Trial: 9858950
Drug: Retarded morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retarded morphine (mean dosage: 49.2 +/- 28.4 mg/d)
Trial: 11788564
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no further therapy)
Trial: 8116539
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g native amylomaize (Hylon‐VII) three times a day for 7 days, containing 28 g type II resistant starch
Trial: 3291491
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml PG E2 endocervical application
Trial: 3291491
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg intravaginal PG E2
Trial: 17905023
Drug: Lidocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine spray
Trial: 26076302
Drug: Ice spray
RxNorm normalized name: Tegrin-LT Lice Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice spray
Trial: 23070146
Drug: Antacid suspension
RxNorm normalized name: Antacid Suspension
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid suspension 20 mL given 2 h after nilotinib 400 mg
Trial: 23070146
Drug: Nilotinib 400
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 400 mg alone
Trial: 20699330
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered chemotherapy
Trial: 16760903
Drug: Electrolyzed-reduced water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyzed-reduced water (ERW) treatment for 6 months
Trial: 16760903
Drug: Vitamin E-coated
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E-coated dialyzer treatment
Trial: 25407026
Drug: Hartmann's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hartmann's solution (HS)
Trial: 29144182
Drug: Plasma-Lyte 148
RxNorm normalized name: Plasma-lyte 148
DrugBank: Gluconic Acid (DB13180)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-Lyte 148 (PL) and Hartmann's solution (HS)
Trial: 23868538
Drug: Volume Guarantee
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume Guarantee (VG) ventilation (Vt=5 mL/kg, PEEP=5 cmH2O)
Trial: 12002664
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol maleate ophthalmic gel-forming solution QD
Trial: 7791837
Drug: Conservative transfusion
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative transfusion regimen (designed to increase hemoglobin level to 10 g per deciliter)
Trial: 2189906
Drug: R 68
RxNorm normalized name: afoxolaner 68 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R 68 151 2% ointment
Trial: 21039597
Drug: Vehicle ointment
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle ointment
Trial: 74662
Drug: gamma-globulin concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gamma-globulin concentrate as adjunctive therapy
Trial: 31313270
Drug: BAY 94-9027
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 94-9027 (extended half-life factor VIII replacement therapy) infused once every 7 days, once every 5 days, or twice weekly
Trial: 24774590
Drug: Conventional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional management of heart failure and an individualized nutritional intervention (optimization of diet, specific recommendations, and nutritional supplements if necessary)
Trial: 15748694
Drug: Ultrasound self-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound self-therapy
Trial: 12452946
Drug: Chewable antacid
RxNorm normalized name: CALCIUM CARBONATE 500 mg ORAL TABLET, CHEWABLE [CALCIUM CARBONATE CHEWABLE ANTACID]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewable antacid tablets (1000 mg CaCO3)
Trial: 12452946
Drug: Active chewable
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active chewable antacid and gums
Trial: 7535996
Drug: 200‐mL boluses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200‐mL boluses of a 6% hydroxyethyl starch solution
Trial: 28756042
Drug: Continue Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue Patch
Trial: 28756042
Drug: Discontinue Patch
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue Patch
Trial: 27117056
Drug: Bevacizumab (BEV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BEV) continuation as a single agent
Trial: 27117056
Drug: No BEV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No BEV (treatment holidays)
Trial: 11789299
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing 67% omega-3 fatty acids (185 mg EPA and 465 mg DHA) in a spread form, 7 grams daily for 12 weeks.
Trial: 8358459
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections
Trial: 2143300
Drug: Akne-Mycyna (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Akne-Mycyna (1% erythromycin), applied twice daily for at least 3 weeks
Trial: 6112131
Drug: Benzodiazepine anxiolytics
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine anxiolytics
Trial: 30149997
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT (100Sn kVp, 70 mAs)
Trial: 30149997
Drug: Standard-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CT (110 kVp, 50 mAs)
Trial: 30149997
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT
Trial: 9024711
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg
Trial: 19451435
Drug: Imatinib (IM)
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib (IM) 400 mg daily
Trial: 16974199
Drug: 0.6 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g/kg ethanol
Trial: 11273587
Drug: High-dose leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose leucovorin (175 mg) with fluorouracil (370 mg/m2)
Trial: 11273587
Drug: Low-dose leucovorin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose leucovorin (25 mg) with fluorouracil (370 mg/m2)
Trial: 11273587
Drug: Levamisole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (50 mg) with fluorouracil and leucovorin
Trial: 11273587
Drug: Weekly treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly treatment regimen
Trial: 11273587
Drug: Monthly treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly treatment regimen
Trial: 7834324
Drug: Terfenadine 120
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 120 mg/day for 21 days
Trial: 2024862
Drug: Aerosol pentamidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol pentamidine, 60 mg per dose, delivered via ultrasonic nebulizer, 5 doses over 14 days followed by maintenance of one dose every 2 weeks.